Alpha Holdings "Oncosec Files Patent Application for Drug Delivery System"

[Asia Economy Reporter Hyunseok Yoo] Oncosec, an affiliate of Alpha Holdings, announced on the 28th that it has filed three patents related to interleukin-12 (IL-12)-based immuno-oncology drugs.

The patents filed this time include TAVO, which is currently in Phase 2 clinical trials for melanoma and triple-negative breast cancer, the next-generation platform TAVOPLUS, and the electroporation system, totaling three.

The company expects the European Patent Office to grant a patent for Oncosec's TAVO. TAVO involves inserting cytokines that activate immune cells combined with DNA plasmids into cancer cells. The patent application in Europe will serve to protect the rights of Oncosec's technology.

Additionally, the European Patent Office is expected to grant additional patent rights for the next-generation platform TAVOPLUS, and the improved electroporation system is a technology capable of treating cancers occurring inside the body, such as in the lungs or liver. Along with this, the Canadian Intellectual Property Office is expected to grant a patent for Oncosec's electroporation system as a pre- and post-operative treatment method for cancer patients.

An Alpha Holdings official stated, “Oncosec is continuously expanding its intellectual property rights, and it is expected that its competitiveness will be strengthened in the long term.”